SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.

Trial Details

NCT ID
NCT05568680
Phase
PHASE1
Sponsor
Verismo Therapeutics
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR
Locations (sample)
  • Tampa, Florida, United States|27.94752,-82.45843
  • Westwood, Kansas, United States|39.04056,-94.6169
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362
  • Houston, Texas, United States|29.76328,-95.36327
  • Madison, Wisconsin, United States|43.07305,-89.40123

Key Eligibility Criteria

  • Pathologically confirmed recurrent or relapsed advanced ovarian cancer, primary peritoneal cancer, fallopian tube cancer, cholangiocarcinoma, or ep…
  • Adult 18 years of age or older.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
  • Has at least 1 measurable lesion by iRECIST for ovarian cancer or cholangiocarcinoma or lesions measurable for mRECIST for mesothelioma.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →